A greater understanding of HIV-associated inflammation and interindividual variations may help to better characterize the neurodegenerative processes in this patient population.
Why this matters
The neuropathogenesis of HIV is commonly characterized by inflammation in people living with HIV (PLHIV) who are virally suppressed on combination antiretroviral treatment (cART).
HIV-associated inflammation may increase the risk of developing neurodegenerative diseases such as Alzheimer’s disease (AD).
AD and other forms of dementia are often characterized by abnormal deposition of cortical amyloid; this neuropathological process could be used as a way to identify aging PLHIV at risk of developing dementia.